1 Biotech Stock to Buy in 2025, and 1 to Avoid
Portfolio Pulse from
Viking Therapeutics and Novavax were notable biotech winners last year, with Viking making clinical progress and Novavax securing a lucrative deal.
February 28, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax's shares rose last year after signing a lucrative deal with a biotech giant, which was well-received by Wall Street.
Novavax's share price increase was driven by a lucrative deal, suggesting strong market confidence and potential for continued success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 50
POSITIVE IMPACT
Viking Therapeutics saw significant share price growth last year due to exciting clinical progress.
Viking Therapeutics' share price increased significantly due to its clinical advancements, indicating positive investor sentiment and potential for future growth.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 50